Teradyne heads into its July 28 earnings report with shorts unwinding, analysts upgrading targets aggressively, and options traders showing the most defensive tilt in weeks — a setup full of competing signals.
The most striking development is the speed of short-seller retreat. Short interest dropped 10% across the past week to 5.5% of the free float, after peaking near 6.4% in late June and early July. A month ago that figure was roughly 4%, meaning the build-and-unwind cycle played out entirely in four weeks. The sharp reversal suggests a tactical rather than structural short position — traders who pressed the stock lower after April's brutal earnings (-23.8% the next day) are now covering ahead of the next print. Borrow conditions give them little incentive to stay: cost to borrow is close to record-cheap at 0.40%, and availability is extraordinarily loose at nearly 3,815% — meaning there are roughly 38 shares available to lend for every one already borrowed. There is no squeeze risk here; the lending market is effectively unconstrained.
Options traders are sending a different message. The put/call ratio climbed to 0.98, roughly two standard deviations above its 20-day average of 0.86 — the most defensive options positioning seen in several weeks and one of the more elevated readings of the past year. That diverges meaningfully from the short-covering trend: while borrowers are backing away, options buyers are purchasing downside protection at an elevated rate. The stock's history explains the caution. The last two earnings prints each produced a negative first-day move, including the April report's nearly 24% drop. Over a five-day window that quarter the stock fell a further 11%. Traders who don't want to hold short positions are instead buying puts to hedge into the July 28 release.
The Street, meanwhile, has become notably more constructive in the past three weeks. Goldman Sachs raised its target to $465 from $350 on July 6, maintaining a Buy. BofA Securities lifted to $525 from $365, Cantor Fitzgerald and Susquehanna both moved to $550, and Baird raised to $446 — all in the span of about two weeks. The consensus target now averages near $423, still above the current price of $353 but below some of the more aggressive Street calls. The bull case centres on AI-driven semiconductor test revenue exceeding 50% of the segment mix, HDD test recovery potentially doubling that revenue line by CY26, and a path to $5 billion in total revenue by CY27. Bears point to lingering weakness in smartphones and datacenter infrastructure, market share erosion risk with key customers, and the robotics segment's slower-than-expected growth. The PE multiple has expanded roughly 7 turns over the past 30 days to above 51x trailing earnings, reflecting the stock's partial recovery from the April collapse — though at those levels, the valuation offers little cushion if the next print disappoints. EV/EBITDA is running near 38.6x. Factor scores show strong analyst recommendation divergence (93rd percentile) but weak forward EPS growth ranking (23rd percentile), a tension the July 28 report will need to resolve.
Semiconductor equipment peers have generally rallied hard this week. UCTT rose 14.3%, FORM gained 9.7%, LRCX added 6.1%, and AMAT climbed 7.4%. Teradyne's 2.9% weekly gain lags all of them — notable given that it carries among the highest analyst target upgrades in the group. That relative underperformance despite bullish analyst revisions points to the market pricing in earnings uncertainty rather than simply tracking the sector move.
Overall, positioning looks cautious rather than complacent: shorts are leaving, but options traders are hedging, the stock trails its peers despite aggressive target lifts, and the July 28 report carries the full weight of a narrative that is either a recovery story or a second consecutive disappointment.
See the live data behind this article on ORTEX.
Open TER on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
